Compare SEMR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEMR | MIRM |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 4.2B |
| IPO Year | 2021 | 2019 |
| Metric | SEMR | MIRM |
|---|---|---|
| Price | $11.88 | $78.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $13.80 | ★ $92.45 |
| AVG Volume (30 Days) | ★ 1.3M | 831.6K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $428,627,000.00 | ★ $471,794,000.00 |
| Revenue This Year | $20.35 | $53.78 |
| Revenue Next Year | $14.87 | $19.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 19.87 | ★ 53.66 |
| 52 Week Low | $6.56 | $36.88 |
| 52 Week High | $18.74 | $82.58 |
| Indicator | SEMR | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 80.18 | 60.79 |
| Support Level | $11.84 | $77.99 |
| Resistance Level | $11.88 | $82.58 |
| Average True Range (ATR) | 0.03 | 3.27 |
| MACD | -0.15 | 1.22 |
| Stochastic Oscillator | 43.75 | 79.12 |
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.